March 6, 2019
In this feature, a panel of IDSA members identifies and critiques important new studies in the current literature that have a significant impact on the practice of infectious diseases medicine.
Reviews in this issue: De-escalation of Anti-MRSA Antimicrobial Therapy for Culture-Negative Pneumonia, A Single-Tablet Antiretroviral Therapy Option in People Living with HIV and End-Stage Renal Disease, and Short-Course, High-Dose Liposomal Amphotericin B for Cryptococcal Meningoencephalitis: A Novel Induction Therapy Strategy?
Tune into the IDSA Facebook page on March 12 at 1 p.m. ET as we premiere our discussion with IDSA Board member Helen Boucher, MD, FIDSA, on antibiotic resistance and the urgent need for new antibiotics.Read More
With evidence that the number of measles cases and outbreaks this year is already well on track to exceed last year’s numbers, the Senate Committee on Health, Education, Labor and Pensions held a hearing on March 5 drawing urgent attention to a central tenet of public health: vaccines save lives.Read More
UnitedHealthcare announced last month that it would once again implement its “soft rejection” policy effective March 1 with modifications based on input from HIVMA and other provider and public health organizations.Read More
IDSA and HIVMA are hosting The Big IDea: Infectious Diseases/HIV Education & Advocacy Day -- our first large scale day of action on Tuesday, Oct. 1 in Washington, DC. Interested in joining us? Sign up here.Read More
IDSA needs your help reaching new members through two initiatives launching this spring -- The Digital Strategy Advisory Group and the Membership Ambassador Program.Read More
When it comes to vaccinations, parents trust the expertise of their doctor more than anyone else. CDC is asking for your help to ensure that all patients are up to date on MMR vaccine.Read More
Infectious Disease News spoke with IDSA spokesperson Matthew Zahn, MD, FIDSA to get his perspective on findings from a recent study published in IDSA’s Clinical Infectious Diseases which reports that “early treatment with oseltamivir was associated with a 30% lower mortality rate compared with later treatment in patients with influenza A(H3N2) during eight recent influenza seasons in Greece.” This is just one of the several news pieces that IDSA and our member spokespersons contributed to. Read others here.Read More